替考拉宁治疗老年患者MRSA肺部感染21例疗效观察

Glycopeptides Antibiotics Teicoplanin in Elder Patients with Lung Infection due to MRSA:Evaluation of Efficacy and Safety

目的评价替考拉宁治疗耐甲氧西林金黄色葡萄球菌(MRSA)肺部感染的老年患者临床疗效和安全性。方法对21例耐甲氧西林金黄色葡萄球菌肺部感染老年患者给予替考拉宁针,第1天400mg静脉滴注,第2天以后每日200mg静脉滴注,连用10～14d治疗,比较治疗前后患者的临床症状、体征、实验室检查及细菌学结果,并判定疗效。结果替考拉宁治疗老年患者MRSA肺部感染临床有效率为81.0%,细菌清除率为85.7%,不良反应发生率为9.5%,不良反应发生率低。结论合理利用替考拉宁治疗老年患者MRSA肺部感染疗效高,安全有效。

OBJECTIVE To evaluate efficacy and safety of glycopeptides antibiotics teicoplanin in elder patients with lung infection due to MRSA. METHODS Twenty-one elderly patients with lung infection due to meticillin-resistant Staphylococcus aereus （MRSA） were treated with teicoplanin 200mg,twice in the first day,then once a day in the following 10-14 days.The therapeutic effect,clearance rate of pathogens,and side effects were compared and evaluated before and after treatment. RESULTS The clinical effective rate of teicoplanin was 81.0%. The clearance rate of MRSA accounted for 85.7% and the side effect rate was 9.5%. In addition,teicoplanin had less side effects. CONCLUSIONS It is high efficacy and safety for teicoplanin to be applied in elder patients with lung infection due to MRSA.